<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67176">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959139</url>
  </required_header>
  <id_info>
    <org_study_id>S1313</org_study_id>
    <secondary_id>NCI-2013-01776</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S1313</secondary_id>
    <nct_id>NCT01959139</nct_id>
  </id_info>
  <brief_title>S1313, Phase IB/II Randomized Study of MFOLFIRINOX + PEGPH20 Vs MFOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modified FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin) is a common
      chemotherapy regimen for patients with metastatic pancreatic adenocarcinoma. Investigators
      want to find out if combining this regimen with another drug, pegylated recombinant human
      hyaluronidase (PEGPH20), will improve overall patient survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase I: Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response (confirmed and unconfirmed, complete and partial)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Carbohydrate Antigen (CA) 19-9 Levels</measure>
    <time_frame>Within 2 years of the end of the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Explore correlation of maximum decrease in CA 19-9 levels to maximum decrease in CA 19-9 levels with overall survival, progression-free survival and response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma expression of hyaluronan (HA)</measure>
    <time_frame>Within 2 years of end of study</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Tumor expression of HA</measure>
    <time_frame>Within 2 years of end of study</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase II: mFOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU) 2,400 mg/m^2, Days 2-4, IV over 46 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: mFOLFIRINOX + PEGPH20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEGPH20, dose to be decided during Phase I, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGPH20</intervention_name>
    <description>3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes</description>
    <arm_group_label>Phase II: mFOLFIRINOX + PEGPH20</arm_group_label>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>Pegylated Recombinant Human Hyaluronidase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m^2, on Day 2, IV over 2 hours</description>
    <arm_group_label>Phase II: mFOLFIRINOX</arm_group_label>
    <arm_group_label>Phase II: mFOLFIRINOX + PEGPH20</arm_group_label>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>NSC-266046</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>400 mg/m^2, on Day 2, IV over 2 hours</description>
    <arm_group_label>Phase II: mFOLFIRINOX</arm_group_label>
    <arm_group_label>Phase II: mFOLFIRINOX + PEGPH20</arm_group_label>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>leucovorin calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m^2, on Day 2, IV over 1.5 hours</description>
    <arm_group_label>Phase II: mFOLFIRINOX</arm_group_label>
    <arm_group_label>Phase II: mFOLFIRINOX + PEGPH20</arm_group_label>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>NSC-616348</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>2,400 mg/m^2, Days 2-4, IV over 46 hours</description>
    <arm_group_label>Phase II: mFOLFIRINOX</arm_group_label>
    <arm_group_label>Phase II: mFOLFIRINOX + PEGPH20</arm_group_label>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
    <other_name>NSC-19893</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS

          -  Newly diagnosed, untreated metastatic histologically or cytologically documented
             pancreatic adenocarcinoma with no known history of brain metastases.

          -  Measurable metastatic disease

          -  No prior treatment with oxaliplatin or irinotecan within 3 years prior to
             registration. Must not have had prior chemotherapy in metastatic setting. Prior
             abdominal radiation therapy is not allowed.

        CLINICAL/LABORATORY

          -  Zubrod Performance Status of 0-1

          -  ANC &gt;/= 1,500/uL

          -  Platelets &gt;/= 100,000/uL

          -  Hemoglobin &gt;/= 9 g/dL

          -  Total bilirubin &lt;/= institutional upper limit of normal (IULN)

          -  AST &lt;/= 2.5 x IULN

          -  ALT &lt;/= 2.5 X IULN

          -  Serum albumin &gt;/= 3 g/dL

          -  Serum creatinine &lt;/= upper limit of normal (ULN) or calculated creatinine clearance &gt;
             50 ml/min

          -  INR &lt;/= 1.2

          -  Not receiving chronic treatment with systemic steroids or other immuno-suppressive
             agent

          -  Not have liver disease such as cirrhosis, chronic active hepatitis or chronic
             persistent hepatitis

          -  Not have active bleeding or a pathological condition that is associated with a high
             risk of bleeding

          -  Must be on active treatment if known history of HIV

          -  No non-malignant medical illnesses that are uncontrolled or whose control may be
             jeopardized by the treatment

          -  No other prior malignancy is allowed except for: adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II
             cancer from which patient is is complete remission, or any other  cancer from which
             the patient has been disease free for five years.

          -  Must not be pregnant or nursing

          -  Tumor (paraffin block or slides) available for submission and will to submit blood
             samples
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramesh K Ramanathan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia G. Piper Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Kaberle</last_name>
    <phone>210-614-8808</phone>
    <email>kkaberle@swog.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Sparks</last_name>
    <phone>210-614-8808</phone>
    <email>dsparks@swog.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Cancer Center at University Medical Center North</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramesh K. Ramanathan</last_name>
      <phone>480-323-1350</phone>
      <email>rrmanathan@tgen.org</email>
    </contact>
    <investigator>
      <last_name>Ramesh K. Ramanathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad Elquza</last_name>
      <phone>520-626-9008</phone>
    </contact>
    <investigator>
      <last_name>Emad Elquza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramesh K. Ramanathan</last_name>
      <phone>480-323-1350</phone>
      <email>rrmanathan@tgen.org</email>
    </contact>
    <investigator>
      <last_name>Ramesh K. Ramanathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz-Josef Lenz</last_name>
      <phone>323-865-3967</phone>
      <email>lenz@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Heinz-Josef Lenz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Howard S. Hochster</last_name>
      <phone>203-785-5702</phone>
      <email>howard.hochster@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Howard S. Hochster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University-Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip A. Philip</last_name>
      <phone>313-576-8746</phone>
      <email>philipp@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Philip A. Philip</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil R. Hingorani</last_name>
      <phone>206-667-6921</phone>
      <email>srh@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Sunil R. Hingorani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
